Ogawa K - Search Results

1

Efficacy and Safety of Immune Checkpoint Inhibitor Combination Therapy for Dysphagia in Patients with Advanced Esophageal Cancer.

Nakayama Y, Ando T, Takagi H, Motoo I, Ueda Y, Sakumura M, Kajiura S, Takahashi S, Shimada S, Takashima Y, Fujinami H, Ogawa K, Tamura H, Hosokawa A, Yasuda I. Nakayama Y, et al. Among authors: ogawa k. J Clin Med. 2024 Aug 15;13(16):4806. doi: 10.3390/jcm13164806. J Clin Med. 2024. PMID: 39200948 Free PMC article.

2

The Efficacy and Safety of Nivolumab Plus mFOLFOX6 in Gastric Cancer with Severe Peritoneal Metastasis.

Nakayama Y, Ando T, Takahashi N, Tsukada K, Takagi H, Goto Y, Nakaya A, Nakada N, Yoshita H, Motoo I, Ueda A, Ueda Y, Sakumura M, Kajiura S, Ogawa K, Hosokawa A, Yasuda I. Nakayama Y, et al. Among authors: ogawa k. J Clin Med. 2024 Jan 31;13(3):834. doi: 10.3390/jcm13030834. J Clin Med. 2024. PMID: 38337528 Free PMC article.

3

Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy.

Ando T, Hosokawa A, Kajiura S, Itaya Y, Ueda A, Fujinami H, Nishikawa J, Kobayashi T, Horikawa N, Tsukioka Y, Yabushita K, Note M, Ogawa K, Sugiyama T. Ando T, et al. Among authors: ogawa k. Gastric Cancer. 2012 Oct;15(4):427-32. doi: 10.1007/s10120-011-0135-0. Epub 2012 Jan 18. Gastric Cancer. 2012. PMID: 22252156 Clinical Trial.

4

Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial.

Ueda A, Hosokawa A, Ogawa K, Yoshita H, Ando T, Kajiura S, Fujinami H, Kawai K, Nishikawa J, Tajiri K, Minemura M, Sugiyama T. Ueda A, et al. Among authors: ogawa k. Onco Targets Ther. 2013 May 8;6:491-6. doi: 10.2147/OTT.S43287. Print 2013. Onco Targets Ther. 2013. PMID: 23690691 Free PMC article.

5

Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.

Kajiura S, Hosokawa A, Yoshita H, Ueda Y, Ueda A, Mihara H, Ando T, Fujinami H, Nishikawa J, Ogawa K, Minemura M, Sugiyama T. Kajiura S, et al. Among authors: ogawa k. Am J Clin Oncol. 2016 Feb;39(1):13-7. doi: 10.1097/COC.0000000000000018. Am J Clin Oncol. 2016. PMID: 24322336 Clinical Trial.

6

Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.

Hosokawa A, Ando T, Ogawa K, Ueda A, Yoshita H, Mihara H, Fujinami H, Kajiura S, Yabushita K, Horikawa N, Kobayashi Y, Yoshioka A, Origasa H, Sugiyama T. Hosokawa A, et al. Among authors: ogawa k. Am J Clin Oncol. 2018 Oct;41(10):977-981. doi: 10.1097/COC.0000000000000405. Am J Clin Oncol. 2018. PMID: 28930775 Clinical Trial.

7

Small intestinal mucosal injury and its risk factors in patients with gastrointestinal cancer who developed complicated fluoropyrimidine-induced diarrhea.

Sakumura M, Ando T, Hosokawa A, Nakajima T, Motoo I, Mihara H, Ueda A, Kajiura S, Nanjo S, Fujinami H, Ogawa K, Yasuda I. Sakumura M, et al. Among authors: ogawa k. BMC Gastroenterol. 2020 Oct 27;20(1):355. doi: 10.1186/s12876-020-01507-5. BMC Gastroenterol. 2020. PMID: 33109089 Free PMC article.

8

Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.

Ando T, Ueda A, Ogawa K, Motoo I, Kajiura S, Nakajima T, Hirano K, Okumura T, Tsukada K, Hara T, Suzuki N, Nakada N, Horikawa N, Fujii T, Yasuda I. Ando T, et al. Among authors: ogawa k. In Vivo. 2021 Jan-Feb;35(1):475-482. doi: 10.21873/invivo.12281. In Vivo. 2021. PMID: 33402499 Free PMC article.

9

Factors, Including Clinical Trial Eligibility, Associated with Induction of Third-Line Treatment for Advanced Gastric Cancer.

Ando T, Hosokawa A, Sakumura M, Motoo I, Kajiura S, Hirano K, Miwa T, Yokota T, Nakada N, Ueda Y, Ueda A, Tsukada K, Ogawa K, Nakaya A, Teramoto A, Nanjo S, Mihara H, Fujinami H, Fujii T, Yasuda I. Ando T, et al. Among authors: ogawa k. Oncology. 2023;101(1):59-68. doi: 10.1159/000526577. Epub 2022 Sep 14. Oncology. 2023. PMID: 36103845

10

Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer.

Motoo I, Ando T, Hamashima T, Kajiura S, Sakumura M, Ueda Y, Murayama A, Ogawa K, Tsukada K, Ueda A, Suzuki N, Nakada N, Nakashima K, Hosokawa A, Yasuda I. Motoo I, et al. Among authors: ogawa k. Front Oncol. 2023 Sep 15;13:1193533. doi: 10.3389/fonc.2023.1193533. eCollection 2023. Front Oncol. 2023. PMID: 37790758 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,723 results

Search Page

Filters